Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 13/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 13/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | IL1B | P01584 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.30 |
| ▸ | TAF1 | P21675 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186231 | 1.00 | KRAS (0.38) | KRASSOS1P2RX7IL1BCHRM2 | |
| SCHEMBL27186885 | 0.85 | KRAS (0.40) | KRASSOS1P2RX7IL1B | |
| SCHEMBL27186887 | 0.85 | KRAS (0.40) | KRASSOS1P2RX7IL1B | |
| SCHEMBL27186376 | 0.84 | SOS1 (0.46) | KRASSOS1 | |
| SCHEMBL27186378 | 0.84 | SOS1 (0.46) | KRASSOS1 | |
| SCHEMBL29844104 | 0.84 | SOS1 (0.46) | KRASSOS1 | |
| SCHEMBL27186280 | 0.83 | KRAS (0.47) | KRASSOS1 | |
| SCHEMBL27186284 | 0.83 | KRAS (0.47) | KRASSOS1 | |
| SCHEMBL29168348 | 0.82 | P2RX7 (0.34) | P2RX7IL1B | |
| SCHEMBL27186257 | 0.79 | KRAS (0.40) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | KRAS 10/4885SOS1 1/4885P2RX7 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.